Search research articles
Contact Us
Filters
Showing results (111-120 of 123) with videos related to
Page
of 13
Sort By:
Annals of Internal Medicine
|
October 1, 1987
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada
W K Evans, R Feld, N Murray, et al.
Oncology (Williston Park, N.Y.)
|
March 1, 1994
Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy
D Osoba, N Murray, K Gelmon, et al.
Statistics in Medicine
|
April 29, 1998
Missing quality of life data in cancer clinical trials: serious problems and challenges
J Bernhard, D F Cella, A S Coates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 16, 1998
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop
N Neymark, W Kiebert, K Torfs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
I F Tannock, D Osoba, M R Stockler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2000
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
B Norris, K I Pritchard, K James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
N Murray, R B Livingston, F A Shepherd, et al.
Cancer Treatment Reports
|
November 1, 1981
Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma
W K Evans, R Feld, G DeBoer, et al.
British Journal of Cancer
|
July 5, 2007
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study
M Mauer, R Stupp, M J B Taphoorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group
J Latreille, J Pater, D Johnston, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 123) with videos related to
Sort By:
Page
of 13
Annals of Internal Medicine
|
October 1, 1987
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada
W K Evans, R Feld, N Murray, et al.
Oncology (Williston Park, N.Y.)
|
March 1, 1994
Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy
D Osoba, N Murray, K Gelmon, et al.
Statistics in Medicine
|
April 29, 1998
Missing quality of life data in cancer clinical trials: serious problems and challenges
J Bernhard, D F Cella, A S Coates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 16, 1998
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop
N Neymark, W Kiebert, K Torfs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
I F Tannock, D Osoba, M R Stockler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2000
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
B Norris, K I Pritchard, K James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
N Murray, R B Livingston, F A Shepherd, et al.
Cancer Treatment Reports
|
November 1, 1981
Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma
W K Evans, R Feld, G DeBoer, et al.
British Journal of Cancer
|
July 5, 2007
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study
M Mauer, R Stupp, M J B Taphoorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group
J Latreille, J Pater, D Johnston, et al.
Page
of 13